Immunology and inflammation

News

In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.

News

Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug discovery operations.

News

Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.

News

Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.

News

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

News

Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.